a7e776a3-4159-4cf7-8e05-2c2202330f58
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- PROTEIN_SECRETION+0.400
- MITOTIC_SPINDLE+0.300
- MTORC1_SIGNALING+0.300
- TGF_BETA_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.300
- COAGULATION-0.300
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_DN-0.300
- MYOGENESIS-0.300
- APOPTOSIS-0.200
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043616 | — | — | 0.897 |
| 2 | MNG1000 | — | — | 0.872 |
| 3 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.870 |
| 4 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.867 |
| 5 | MDT-AP-0167 | Med | Medulloblastoma | 0.866 |
| 6 | TCGA-C8-A137-01A-11R-A115-07 | — | C | 0.864 |
| 7 | MNG1011 | — | — | 0.860 |
| 8 | MNG409 | — | — | 0.859 |
| 9 | MNG1063 | — | — | 0.850 |
| 10 | SRR5088878 | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |